About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

Active Not RecruitingNCT04519580

Improved Diagnostics and Monitoring of Polymyalgia Rheumatica

Background: Polymyalgia rheumatica (PMR) is characterised by pain of the proximal muscles, general symptoms, and raised inflammatory markers. Treatment with prednisolone has several adverse effects. P...

Lead sponsor: Kresten Krarup Keller•3 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Kresten Krarup Keller

Collaborators

Aarhus University Hospital

Age

50 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patients suspected of PMR.
•Age above 50
•Pain of the proximal muscles.

Exclusion Criteria

•Peroral, intraarticular, intramuscular and dermal application of glucocorticoids within the last 3 month.
•Previous prednisolone treatment for GCA/PMR
•Unable to give consent.
•Symptoms of GCA (headache, jaw claudication, vision disturbances).
•Active malignant cancers within the last 5 years (except basal cell carcinoma).
•Other inflammatory rheumatic diseases (eg. rheumatoid arthritis, polymyositis, spondyloarthritis, psoriatic arthritits, gout).
•Uncontrolled diseases (eg severe active astma, cardiac disease with NYHA class IV)
•Treatment with peroral oestrogens, aminogluthethimid, trilostan, ketoconazole, fluconazol, etomidate, phenobarbital, phenytoin, rifampicin, metyrapon, mitotane.
•Known primary or secondary adrenal insufficiency.

Related studies

RECRUITINGPhase 3

Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica

NCT07279688 · Polymyalgia Rheumatica (PMR)

Evaluation of Children With Endocrine and Metabolic-Related Conditions

NCT02769975 · Adrenal Insufficiency, Growth Disorder, and more

The VGR GCA Cohort: Ultrasound, Biopsy and Biomarkers - Novel Methods for Diagnosis, Monitoring and Prognosis in Giant Cell Arteritis.

NCT07246577 · Giant Cell Arteritis (GCA)

Association of Ultrasonographic Temporal Artery Lesions and Relapse in Patients With Giant Cell Arteritis

NCT06894602 · Giant Cell Arteritis

Updated Diagnostic Cortisol Values for Adrenal Insufficiency

NCT05149638 · Adrenal Insufficiency

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: September 24, 2025Terms

Trial snapshot

StatusACTIVE_NOT_RECRUITING

Phase—

Enrollment98

Start dateSep 2020

Last updatedSep 24, 2025

Condition

Polymyalgia Rheumatica Giant Cell Arteritis Adrenal Insufficiency

Locations shown

Department of Rheumatology, Aarhus University Hospital

Aarhus

Department of Rheumatology, Horsens Regional Hospital

Horsens

Diagnostic Centre, Silkeborg Regional Hospital

Silkeborg

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 24, 2025Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions